A detailed history of Td Asset Management Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 204,998 shares of CRNX stock, worth $10.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
204,998
Previous 235,198 12.84%
Holding current value
$10.4 Million
Previous $11 Million 16.6%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

SELL
$42.12 - $51.91 $1.27 Million - $1.57 Million
-30,200 Reduced 12.84%
204,998 $9.18 Million
Q1 2024

May 08, 2024

BUY
$34.76 - $46.81 $2.04 Million - $2.75 Million
58,772 Added 33.31%
235,198 $11 Million
Q4 2023

Feb 12, 2024

BUY
$25.62 - $37.07 $947,940 - $1.37 Million
37,000 Added 26.54%
176,426 $6.28 Million
Q3 2023

Oct 27, 2023

BUY
$15.97 - $30.59 $1.29 Million - $2.46 Million
80,526 Added 136.72%
139,426 $4.15 Million
Q2 2023

Aug 09, 2023

BUY
$15.73 - $23.6 $492,349 - $738,680
31,300 Added 113.41%
58,900 $1.06 Million
Q1 2023

May 10, 2023

BUY
$15.31 - $21.1 $422,556 - $582,360
27,600 New
27,600 $443,000
Q3 2019

Nov 07, 2019

SELL
$14.91 - $25.01 $125,527 - $210,559
-8,419 Closed
0 $0
Q2 2019

Aug 01, 2019

BUY
$21.48 - $27.71 $180,840 - $233,290
8,419 New
8,419 $210,000
Q1 2019

May 08, 2019

SELL
$21.07 - $29.31 $202,672 - $281,932
-9,619 Closed
0 $0
Q4 2018

Feb 01, 2019

SELL
$22.4 - $35.39 $29,119 - $46,007
-1,300 Reduced 11.91%
9,619 $288,000
Q3 2018

Nov 01, 2018

BUY
$22.66 - $36.8 $247,424 - $401,819
10,919 New
10,919 $313,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.73B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.